News|Articles|November 20, 2026

EU Approves Sanofi's Rabies Vaccine VaxRabeo for All Age Groups

The European Commission has approved VaxRabeo (rabies virus, inactivated, Wistar strain; Sanofi) for pre-exposure prophylaxis (PrEP) and postexposure prophylaxis (PEP) against rabies in individuals of all ages. The decision, announced November 19, 2026, is the first marketing authorization for the vaccine and follows a positive opinion from the Committee for Medicinal Products for Human Use on September 17, 2026.1,2 VaxRabeo is produced with Vero cell technology and uses the same Wistar rabies strain as Sanofi's existing vaccines Verorab and Imovax Rabies. The company said the formulation is designed to minimize the risk of allergic reactions.1

The vaccine can be given on the 2-dose PrEP schedule and the 4-dose PEP schedule recommended by the World Health Organization (WHO), with or without rabies immunoglobulin.1

A European Commission marketing authorization is valid in all European Union member states, as well as in Iceland, Liechtenstein, and Norway. For clinicians, the decision adds a newer-generation option from the same Wistar strain lineage for both travelers seeking PrEP and patients who need PEP after a potential exposure.1,2

Clinical Program Compared VaxRabeo With Existing Vaccines

Sanofi's clinical development program compared VaxRabeo with Verorab and Imovax Rabies in both PrEP and PEP settings. In PrEP studies, 2-dose and 3-dose regimens produced comparable protective antibody levels in adults and children.1

Booster doses given at 12 months or at 24 to 36 months after primary vaccination produced strong responses, which the company described as high boostability. In PEP studies, VaxRabeo showed immunogenicity similar to the comparator vaccines, and 100% of participants receiving intramuscular doses reached protective antibody levels.1

The safety profile was consistent with existing rabies vaccines, and no significant safety concerns emerged across the program.1 VaxRabeo has a shelf life of 60 months and remains stable at temperatures up to 27 °C for 96 hours before reconstitution.1 The release did not include individual study names, enrollment figures, or a citation to peer-reviewed results, so the size of each comparison cannot yet be assessed independently.

Global Rabies Burden Remains High

Rabies is present in 150 countries and causes an estimated 59,000 deaths each year, according to WHO figures cited by Sanofi.1 About 29 million people receive PEP annually, and roughly 40% of people bitten by animals suspected of having rabies are children younger than 15 years.1

Travelers also face exposure risk, estimated at about 0.4% per month of stay in areas where rabies is present.1 Sanofi has supplied rabies vaccines for 5 decades, and the company describes VaxRabeo as a next-generation vaccine built on this experience.1 Timely PEP after a bite or scratch from a suspect animal remains the main way to prevent death once exposure occurs.1

"Death from rabies should be prevented at all costs; it is entirely preventable with vaccination provided on time," Thomas Triomphe, head of vaccines at Sanofi, said in a statement. "This first approval of VaxRabeo is a proud milestone for Sanofi and reflects our commitment to rabies protection, built on five decades of expertise and innovation."1

"With VaxRabeo, we are bringing a next-generation rabies vaccine to healthcare systems and patients," Triomphe said.1 The announcement did not include launch timing for individual European Union member states.

References
  1. Press release: Sanofi's next-generation rabies vaccine VaxRabeo approved in the EU for all ages. News release. Sanofi. November 19, 2026. Accessed November 19, 2026. https://www.globenewswire.com/news-release/2026/11/19/3406292/0/en/press-release-sanofi-s-next-generation-rabies-vaccine-vaxrabeo-approved-in-the-eu-for-all-ages.html
  2. VaxRabeo. European Medicines Agency. Accessed November 19, 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/vaxrabeo

Related to this article

Measles Update: November 13, 2026
The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.